Abstract: A fetal scalp monitor is disclosed that enables a medical professional to monitor the well-being of a fetus in utero. The fetal scalp monitor has a main body, with a central core having a temperature sensor, conductive dome, grounding ring, and tocodynamometer. The main body also has at least one adhesive portion to facilitate the attachment of the device onto the scalp of a fetus, and a plurality of concentric rings to militate against amniotic fluids from entering the adhesive portion. The vital signs of the infant and conditions inside the uterus are then transmitted, either wired or wirelessly, to a fetus monitoring device.

Abstract: A method of treating an ischemic event in tissue of a subject in need thereof, includes applying light to a tissue susceptible to ischemic reperfusion injury, the light having a wavelength selected from two wavelength ranges selected from 730-770 nm, 850-890 nm, 880-920 nm, and 930-970 nm, thereby to reduce ischemic reperfusion injury in the tissue of the subject.

Abstract: A fetal scalp monitor is disclosed that enables a medical professional to monitor the well-being of a fetus in utero. The fetal scalp monitor has a main body, with a central core having a temperature sensor, conductive dome, grounding ring, and tocodynamometer. The main body also has at least one adhesive portion to facilitate the attachment of the device onto the scalp of a fetus, and a plurality of concentric rings to militate against amniotic fluids from entering the adhesive portion. The vital signs of the infant and conditions inside the uterus are then transmitted, either wired or wirelessly, to a fetus monitoring device.

Abstract: A method of treating an ischemic event in tissue of a subject in need thereof, includes applying light to a tissue susceptible to ischemic reperfusion injury, the light having a wavelength selected from two wavelength ranges selected from 730-770 nm, 850-890 nm, 880-920 nm, and 930-970 nm, thereby to reduce ischemic reperfusion injury in the tissue of the subject.

Abstract: A light therapy method, comprising identifying a pathological condition in a patient, selecting at least one light wavelength based on the identified pathological condition, and applying one or a combination of the selected light wavelengths to the patient using a light source.

Abstract: An exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event. Applying the light to the tissue inhibits cytochrome c oxidase activity. Another exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event and prior to either reoxygenation of the tissue or clinical intervention to reduce cell damage. An exemplary light therapy device includes at least one light source configured to generate light having a wavelength of at least one of approximately 730-770 nm, 850-890 nm, 880-920 nm, and 930-970 nm.

Abstract: A light therapy method, comprising identifying a pathological condition in a patient, selecting at least one light wavelength based on the identified pathological condition, and applying one or a combination of the selected light wavelengths to the patient using a light source.

Abstract: An exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event. Applying the light to the tissue inhibits cytochrome c oxidase activity. Another exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event and prior to either reoxygenation of the tissue or clinical intervention to reduce cell damage. An exemplary light therapy device includes at least one light source configured to generate light having a wavelength of at least one of approximately 730-770 nm, 850-890 nm, 880-920 nm, and 930-970 nm.

Abstract: An exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event. Applying the light to the tissue inhibits cytochrome c oxidase activity. Another exemplary method includes selecting at least one light source configured to generate light at a particular wavelength and applying the light to tissue following an ischemic event and prior to either reoxygenation of the tissue or clinical intervention to reduce cell damage. An exemplary light therapy device includes at least one light source configured to generate light having a wavelength of at least one of approximately 730-770 nm, 850-890 nm, 880-920 nm, and 930-970 nm.

Abstract: A method to detect a messenger ribonucleic acid (mRNA) sequence is provided including annealing a first probe and a second probe to at least a portion of the mRNA, wherein the first and second probes do not comprise the same nucleotide sequence, wherein each probe sequence is complimentary to at least a portion of the mRNA and the second probe is a T-shaped probe having 1) a probe sequence complementary to at least a portion of the mRNA sequence and 2) a rolling circle amplification primer that is linked to an internal reactive group of the probe sequence of the second probe so as to provide physical separation of probe ligation and rolling circle amplification, said probe-connected rolling circle primer comprising a circle recognition sequence.

Abstract: Certain embodiments of the present invention relate to methods for detecting DNA or RNA (including, but not limited to, mRNA).

Abstract: Certain embodiments of the present invention relate to methods for detecting lung cancer.

Abstract: Certain embodiments of the present invention relate to methods for detecting lung cancer.